Table 3 eGFR equation performance in enabling accurate CKD staging (G1, G2, G3a, G3b, G4, G5). (To be placed after ‘Results’ subsection ‘CKD Staging performance by eGFR equations’)
Subgroup | Samples (N) | Equation | Correct CKD Staginga | Error in CKD Staging | |
|---|---|---|---|---|---|
Underestimation of CKD severity | Overestimation of CKD severity | ||||
Overall | 205 | eGFRcr(ASR) | 98 (47.8%) | 64 (31.2%) | 43 (21.0%) |
eGFRcr(AS) | 104 (50.7%) | 74 (36.1%) | 27 (13.2%) | ||
eGFRcr-cys(ASR) | 104 (50.7%) | 23 (11.3%) | 78 (38.0%) | ||
eGFRcr-cys(AS) | 109 (53.2%) | 31 (15.1%) | 65 (31.7%) | ||
GFRNMR | 120 (58.5%) | 37 (18.1%) | 48 (23.4%) | ||
Preserved liver function | 143 | eGFRcr(ASR) | 78 (54.5%) | 26 (18.2%) | 39 (27.3%) |
eGFRcr(AS) | 84 (58.7%) | 34 (23.8%) | 25 (17.5%) | ||
eGFRcr-cys(ASR) | 67 (46.9%) | 8 (5.5%) | 68 (47.6%) | ||
eGFRcr-cys(AS) | 71 (49.7%) | 14 (9.7%) | 58 (40.6%) | ||
GFRNMR | 85 (59.4%) | 22 (15.4%) | 36 (25.2%) | ||
Reduced liver function | 60 | eGFRcr(ASR) | 20 (33.3%)* | 36 (60.0%) | 4 (6.7%) |
eGFRcr(AS) | 20 (33.3%)* | 38 (63.3%) | 2 (3.4%) | ||
eGFRcr-cys(ASR) | 35 (58.3%) | 15 (25.0%) | 10 (16.7%) | ||
eGFRcr-cys(AS) | 36 (60.0%) | 17 (28.3%) | 7 (11.7%) | ||
GFRNMR | 33 (55.0%) | 15 (25.0%) | 12 (20.0%) | ||
MELD ≤ 15 | 148 | eGFRcr(ASR) | 78 (52.7%) | 37 (25.0%) | 33 (22.3%) |
eGFRcr(AS) | 80 (54.1%) | 46 (31.1%) | 22 (14.8%) | ||
eGFRcr-cys(ASR) | 73 (49.3%) | 12 (8.1%) | 63 (42.6%) | ||
eGFRcr-cys(AS) | 76 (51.4%) | 20 (13.5%) | 52 (35.1%) | ||
GFRNMR | 87 (58.8%) | 26 (17.6%) | 35 (23.6%) | ||
MELD > 15 | 49 | eGFRcr(ASR) | 18 (36.7%) | 21 (42.9%) | 10 (20.4%) |
eGFRcr(AS) | 22 (44.9%) | 22 (44.9%) | 5 (10.2%) | ||
eGFRcr-cys(ASR) | 26 (53.1%) | 9 (18.4%) | 14 (28.5%) | ||
eGFRcr-cys(AS) | 28 (57.1%) | 9 (18.4%) | 12 (24.5%) | ||
GFRNMR | 28 (57.1%) | 9 (18.4%) | 12 (24.5%) | ||
Ascites not present | 163 | eGFRcr(ASR) | 86 (52.8%) | 35 (21.5%) | 42 (25.7%) |
eGFRcr(AS) | 93 (57.1%) | 43 (26.4%) | 27 (16.5%) | ||
eGFRcr-cys(ASR) | 80 (49.1%) | 11 (6.7%) | 72 (44.2%) | ||
eGFRcr-cys(AS) | 84 (51.5%) | 18 (11.1%) | 61 (37.4%) | ||
GFRNMR | 97 (59.5%) | 26 (16.0%) | 40 (24.5%) | ||
Ascites present | 42 | eGFRcr(ASR) | 12 (28.6%)* | 29 (69.0%) | 1 (2.4%) |
eGFRcr(AS) | 11 (26.2%)* | 31 (73.8%) | 0 (0.0%) | ||
eGFRcr-cys(ASR) | 24 (57.1%) | 12 (28.6%) | 6 (14.3%) | ||
eGFRcr-cys(AS) | 25 (59.5%) | 13 (31.0%) | 4 (9.5%) | ||
GFRNMR | 23 (54.8%) | 11 (26.2%) | 8 (19.0%) | ||
mGFR ≥ 60b | 96 | eGFRcr(ASR) | 56 (58.3%) | 21 (21.9%) | 19 (19.8%) |
eGFRcr(AS) | 59 (61.5%) | 24 (25.0%) | 13 (13.5%) | ||
eGFRcr-cys(ASR) | 53 (55.2%) | 4 (4.2%) | 39 (40.6%) | ||
eGFRcr-cys(AS) | 61 (63.5%) | 6 (6.2%) | 29 (30.3%) | ||
GFRNMR | 57 (59.4%) | 6 (6.2%) | 33 (34.4%) | ||
mGFR < 60b | 109 | eGFRcr(ASR) | 42 (38.5%)* | 43 (39.4%) | 24 (22.1%) |
eGFRcr(AS) | 45 (41.3%)* | 50 (45.9%) | 14 (12.8%) | ||
eGFRcr-cys(ASR) | 51 (46.8%) | 19 (17.4%) | 39 (35.8%) | ||
eGFRcr-cys(AS) | 48 (44.0%) | 25 (23.0%) | 36 (33.0%) | ||
GFRNMR | 63 (57.8%) | 31 (28.4%) | 15 (13.8%) | ||